Elkedonia

📍 Strasbourg, France🗓 Founded 2025👥 4 employees💰 Last funded Jun 2025
Biotechnology Research
LinkedIn
Elkedonia is a pioneering start-up company committed to transforming the treatment of mental health disorders. Our mission is to develop a new generation of antidepressants that are fast-acting, highly effective, and safe. Our breakthrough approach is based on first-in-class neuroplastogens, which promote neuroplasticity without the side effects of psychedelics and ketamine. By eliminating risks of dependence, sedation, or psychotic effects, our innovative treatments empower patients to rediscover the joys of life while significantly reducing the risk of relapse and suicide. At Elkedonia, we believe in a future where mental health treatments enhance well-being without compromise. Join us in this therapeutic revolution. 🧠 Innovating for better mental health.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2025
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Elkedonia?
Elkedonia has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Elkedonia last raise funding?
The most recent investment in Elkedonia recorded on gritt.io was in June 2025.
When was Elkedonia founded?
Elkedonia was founded in 2025.
What industry is Elkedonia in?
Elkedonia operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Elkedonia based?
Elkedonia is headquartered in Strasbourg, France.